Karolinska Institute

DAVOS ALZHEIMER’S COLLABORATIVE ANNOUNCES STRATEGIC PARTNERSHIP WITH THE FINGERS BRAIN HEALTH INSTITUTE AND ITS WORLD-WIDE FINGERS GLOBAL SCIENTIFIC COORDINATING CENTER TO ADVANCE STUDIES ON DELAYING ALZHEIMER’S PROGRESSION

Retrieved on: 
Tuesday, November 1, 2022
Awareness, Government budget balance, Alzheimer Research Forum, DAC, Karolinska Institute, Doctor of Philosophy, Center, Dementia, Partnership, Clinical trial, Cognitive deficit, Board, Research, GLOBE, Risk, Physician, Disease, RCT, Randomized controlled trial, Fisher Center for Alzheimer's Research Foundation, World Economic Forum, Ageing, Davos, Indian Computing Olympiad, Patient, Conditional sentence, Global, Caregiver, Medical device, Pharmaceutical industry, MD, Disability

The partnership between DAC, FBHI and its World-Wide FINGERS Global Scientific Coordinating Center, serves as an opportunity to educate and engage physicians and consumers on risk reduction measures.

Key Points: 
  • The partnership between DAC, FBHI and its World-Wide FINGERS Global Scientific Coordinating Center, serves as an opportunity to educate and engage physicians and consumers on risk reduction measures.
  • We are excited to join forces with FBHI and its World-Wide FINGERS Global Scientific Coordinating Center to advance prevention studies around the world, beginning in Kenya, where rates of Alzheimers are growing, said George Vradenburg, Founding Chairman ofthe Board, Davos Alzheimers Collaborative.
  • FBHI hosts and runs the World Wide FINGERS Global Coordination Center, a central resource for the World Wide FINGERS Network.
  • The Global Coordination Center supports the global scientific activities of the World Wide FINGERS Network, including network coordination, clinical trial optimization, and joint analysis of data.

Shuttle Pharmaceuticals Appoints Bette Jacobs to its Board of Directors

Retrieved on: 
Tuesday, November 1, 2022
Honda, Survival, Board of directors, Risk, IPO, California State University, Faculty, Cherokee Nation, SEC, Anhui University, Cancer, Karolinska Institute, Research, Board, RT, Tokyo Medical and Dental University, Nasdaq, University of British Columbia, Immunotherapy, National Coalition for Syrian Revolutionary and Opposition Forces, Cherokee, Lijun International Pharmaceutical (Holding) Co. Ltd., University, National Institute of General Medical Sciences, Radiation, Patient, Audit committee, National, Georgetown University School of Medicine, Ecology, Sciences Po, Georgetown University, Quality of life, Chang Gung University, Georgetown University School of Nursing and Health Studies, Moses Austin, Pharmaceutical industry, Nursing

ROCKVILLE, Md., Nov. 1, 2022 /PRNewswire/ --Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced the appointment of Dr. Bette Jacobs to its Board of Directors as an independent director.

Key Points: 
  • ROCKVILLE, Md., Nov. 1, 2022 /PRNewswire/ --Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced the appointment of Dr. Bette Jacobs to its Board of Directors as an independent director.
  • Dr. Jacobs will serve on the Audit Committee and the Nominating and Corporate Governance Committee.
  • A voting member of the Cherokee Nation, Dr. Jacobs has lifetime involvement in advancing equity and diversity programs.
  • "I am excited to welcome Dr. Bette Jacobs to the board at Shuttle Pharmaceuticals," Dr. Anatoly Dritschilo, Chief Executive Officer of Shuttle Pharmaceuticals, said.

Cerecin appoints Dr. Marc Cantillon as Chief Medical Officer

Retrieved on: 
Monday, October 10, 2022
Merck, Therapy, VP, Food and Drug Administration Amendments Act of 2007, Cornell University, University, Kyowa Hakko Kirin, Peripheral nervous system, CEO, Geriatrics, Translation, Psychiatry, Wharton School of the University of Pennsylvania, Karolinska Institute, Athena, Drug development, Wilmar International, Lists of diseases, Investment, Internal medicine, Company, IP, GLOBE, CMO, Critical Path Institute, Schering, University of Pennsylvania, AstraZeneca, Risk, PD, Growth, Business administration, Research, Icahn School of Medicine at Mount Sinai, Neurology, CNS, AD, Neurodegeneration, Coalition, Central nervous system, Migraine, Genomics, Patient, Kyōwa, Partnership, North American Medical Management, Food, MD, Forward-looking statement, Insomnia, Mount Sinai, Pharmaceutical industry, Medicine, Pfizer, Sanofi

Cerecin expands senior management team with appointment of Dr. Marc Cantillon as Chief Medical Officer

Key Points: 
  • Cerecin expands senior management team with appointment of Dr. Marc Cantillon as Chief Medical Officer
    Dr. Cantillon brings over 25 years experience in senior Central Nervous System (CNS) development roles at Merck, Pfizer, Kyowa and Reviva Pharmaceuticals
    SINGAPORE and DENVER, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Cerecin, Inc. a clinical-stage biotechnology company pioneering innovative neurotherapeutics, today announced the appointment of Marc Cantillon, MD, as Chief Medical Officer (CMO) of the Company.
  • Prior to this, Dr. Cantillon was Chief Medical Officer of Green Valley Pharmaceuticals, a biopharmaceutical company developing carbohydrate drugs in Parkinsonss Disease (PD) and Alzheimers Disease (AD).
  • Commenting on the appointment, Charles Stacey, CEO of Cerecin, said, We are very pleased to welcome Marc to our executive team.
  • Dr. Marc Cantillon, CMO of Cerecin, said, Cerecins metabolic approach to neurodegenerative disease has the potential to deliver novel treatment options to patients across several disease areas.

Gonçalo Castelo-Branco receives the Hans Wigzell Research Foundation's science prize amounting to SEK 925,000

Retrieved on: 
Friday, September 16, 2022
Swedish Foundation for Strategic Research, Royal Swedish Academy of Sciences, Infectious Diseases Institute, Multiple sclerosis, Karolinska Institute, National Society for Medical Research, Department, University, Brain, Eric, SSMF, Chemistry (relationship), Anglo-Swedish Society, MS, Chromatin, SEK, Value Partners (asset management), Cell, Medical research, European Research Council, B cell, Doctor of Philosophy, Degenerative disease, Rolf Schock Prizes, UCL Faculty of Engineering Sciences, Science, IVA, Research, DNA, Biophysics, Neuron, KI, Nobel Committee, Education, Disease, Epigenomics, Pharmaceutical industry, Medicine

STOCKHOLM, Sept. 16, 2022 /PRNewswire/ --The Hans Wigzell Research Foundation (Hans Wigzells Forskningsstiftelse) awards its annual scientific prize to Professor Gonalo Castelo-Branco at Karolinska Institutet (KI).

Key Points: 
  • STOCKHOLM, Sept. 16, 2022 /PRNewswire/ --The Hans Wigzell Research Foundation (Hans Wigzells Forskningsstiftelse) awards its annual scientific prize to Professor Gonalo Castelo-Branco at Karolinska Institutet (KI).
  • Professor Gonalo Castelo-Branco receives the prize of SEK 925,000 for his important research around oligodendrocytes a cell type which plays important roles in relation to how the human brain develops and functions.
  • In his research, Professor Castelo-Branco has shown how a cell's DNA can be controlled to develop into an oligodendrocyte.
  • His research has already helped build a better understanding of multiple sclerosis (MS) and can hopefully also lead to improved therapy against this difficult disease.

Co-Author of the Karolinska 1000 Consecutive MANTA® Vascular Closure Device Study to Present Learnings at the Transcatheter Cardiovascular Therapeutics (TCT) 2022 Conference

Retrieved on: 
Thursday, September 15, 2022
Weck, Health, MANTA, Karolinska Institute, NYSE, Canadian International Council, SAFE, Anesthesia, VCDS, CRF, Percutaneous, Device, LMA, Interventional cardiology, TAVI, U.S. Securities and Exchange Commission, Patient, Emergency medicine, Karolinska University Hospital, Solution, Annual report, Clinical trial, Teleflex, VCD, International Journal of Cardiology, Security (finance), 1048, Observational study, GLOBE, Prostatic urethral lift, Urology, Catheter, Veni, vidi, vici, TFX, TCT, Radiology, MARVEL, Medical device, Medical imaging, Cardiology, Pilling, QuikClot

TCT is the Cardiovascular Research Foundation's (CRF) annual scientific symposium and the world's foremost educational forum specializing in interventional cardiovascular medicine.

Key Points: 
  • TCT is the Cardiovascular Research Foundation's (CRF) annual scientific symposium and the world's foremost educational forum specializing in interventional cardiovascular medicine.
  • The findings of our study indicate that the MANTA Device is easy to learn and has a short learning curve, which is in line with our user experience.
  • The MANTA Device is the first commercially available biomechanical vascular closure device designed specifically for large bore femoral arterial access site closure.
  • Percutaneous plug-based vascular closure device in 1000 consecutive transfemoral transcatheter aortic valve implantations.

Pretzel Therapeutics Launches With $72.5 Million Series A Financing to Pioneer Mitochondrial Therapies

Retrieved on: 
Monday, September 12, 2022
Biotechnology, Genetics, Health, Lists of diseases, MRC Mitochondrial Biology Unit, Senior advisor, Ageing, Industry, Business, Salk Institute for Biological Studies, ROME, Drug development, ISCB Senior Scientist Award, HealthCap, Plasma protein binding, Degenerative disease, Enzyme, Mitochondrial disease, Coronavirus Scientific Advisory Board (Turkey), Norwest Venture Partners, IPO, MBA, Praxis, University of Cambridge, DNA, Karolinska Institute, MRC, Chemistry (relationship), Senior, Biotechnology, AstraZeneca, University of Gothenburg, Roberto Minczuk, Board, Biophysics, Business development, Genome, Drug discovery, Therapy, Department, MA, GV, Vertex Pharmaceuticals, Laboratory, Pretzel, University, Pharmaceutical industry, Management, Director, Genetics, U.S. Venture Partners, Chemistry, DRS

Pretzel Therapeutics , a biotechnology company harnessing the intricacies of mitochondrial biology to develop groundbreaking therapies, launched today with a $72.5 million Series A financing to pioneer novel therapies to modulate mitochondrial function.

Key Points: 
  • Pretzel Therapeutics , a biotechnology company harnessing the intricacies of mitochondrial biology to develop groundbreaking therapies, launched today with a $72.5 million Series A financing to pioneer novel therapies to modulate mitochondrial function.
  • We are excited to pioneer a new era in the treatment of diseases related to mitochondrial dysfunction.
  • Pretzels platform encompasses three primary technologies to modulate mitochondrial function: Genome correction, genome expression modulation, and mitochondrial quality control.
  • The companys genome correction therapeutics will utilize specialized gene-editing tools to reduce mutated mitochondrial DNA and increase the levels of healthy mitochondrial DNA.

NeoDynamics received FDA clearance for pulse biopsy system NeoNavia®

Retrieved on: 
Thursday, September 8, 2022
Breast cancer, Breast, Needle, CEO, Medtech, Research, NEOD, Karolinska Institutet Prize for Research in Medical Education, Neoplasm, US Foods, Food, Diagnosis, Biopsy, Karolinska Institute, Lymph, Axilla, Nasdaq, FDA, CE, Marketing, Patient, Medical device, Pharmaceutical industry, Medical imaging

STOCKHOLM, Sept. 8, 2022 /PRNewswire/ -- The MedTech company NeoDynamics has today received approval for its innovative pulse biopsy system NeoNavia from the US Food and Drug Administration, FDA.

Key Points: 
  • STOCKHOLM, Sept. 8, 2022 /PRNewswire/ -- The MedTech company NeoDynamics has today received approval for its innovative pulse biopsy system NeoNavia from the US Food and Drug Administration, FDA.
  • "The FDA approval for NeoNavia is a major milestone for NeoDynamics and a stamp of quality for both the product and NeoDynamics as a whole," said Anna Eriksrud, CEO of NeoDynamics.
  • The company's first product NeoNavia, a new innovative pulse biopsy system for ultrasound guided tissue sampling, is currently being introduced to the market.
  • NeoNavia is a modern biopsy system with a completely new patented pulse technology intended for ultrasound-guided tissue sampling.

NeoDynamics received FDA clearance for pulse biopsy system NeoNavia®

Retrieved on: 
Thursday, September 8, 2022
Breast cancer, Breast, Needle, CEO, Medtech, Research, NEOD, Karolinska Institutet Prize for Research in Medical Education, Neoplasm, US Foods, Food, Diagnosis, Biopsy, Karolinska Institute, Lymph, Axilla, Nasdaq, FDA, CE, Marketing, Patient, Medical device, Pharmaceutical industry, Medical imaging

STOCKHOLM, Sept. 8, 2022 /PRNewswire/ -- The MedTech company NeoDynamics has today received approval for its innovative pulse biopsy system NeoNavia from the US Food and Drug Administration, FDA.

Key Points: 
  • STOCKHOLM, Sept. 8, 2022 /PRNewswire/ -- The MedTech company NeoDynamics has today received approval for its innovative pulse biopsy system NeoNavia from the US Food and Drug Administration, FDA.
  • "The FDA approval for NeoNavia is a major milestone for NeoDynamics and a stamp of quality for both the product and NeoDynamics as a whole," said Anna Eriksrud, CEO of NeoDynamics.
  • The company's first product NeoNavia, a new innovative pulse biopsy system for ultrasound guided tissue sampling, is currently being introduced to the market.
  • NeoNavia is a modern biopsy system with a completely new patented pulse technology intended for ultrasound-guided tissue sampling.

Bruker Launches New nanoElute® 2 nano-LC For 4D-Proteomics, Advances Fluxomics Applications with MetaboScape® 2023 Software

Retrieved on: 
Monday, August 29, 2022
Software, Research, General Health, Pharmaceutical, Hardware, Medical Devices, Technology, Health Technology, Science, Biotechnology, Neurology, Health, Machine learning, Molecular biology, Metabolomics, University, Paser, Lipid, Research, Proteomics, University of Southern Denmark, Life, Protein, Associate, Disease, Solution, MOMA, Pathology, Department, JHSPH Department of Biochemistry and Molecular Biology, Bruker, Mass spectrometry, PPI, Workflow, Biochemistry, Cell, Multimedia, Capillary, Microscopy, Plasma, Karolinska Institute, Nasdaq, IMSC, MALDI, University of Ottawa, CCS, Conference, Cell biology, Risk, Â, International Mass Spectrometry Foundation, Acquisition, ISCB Senior Scientist Award, Mobile phone, Fine chemical, Medical imaging, Cancer

The nanoElute 2 features a further improved nano-LC pump design, and an intuitive and flexible user interface covering a broad range of applications from single-cell proteomics to plasma proteomics.

Key Points: 
  • The nanoElute 2 features a further improved nano-LC pump design, and an intuitive and flexible user interface covering a broad range of applications from single-cell proteomics to plasma proteomics.
  • The nanoElute 2 now also supports the label-free ProteoCHIP for the CellenONE platform for high-sensitivity single cell proteomics.
  • The nanoElute 2 dissolves the tryptic peptides directly in the plate prior to injection, avoiding manual intervention and thus streamlining our workflows.
  • Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life.

mRNA Leading Expert Kenneth Chien and Novalis LifeSciences’ Marijn Dekkers Investing EUR 39M Series B2 Financing in mRNA Technology Platform Company eTheRNA

Retrieved on: 
Tuesday, August 23, 2022
COO, Partnership, COVID-19, CEO, Thermo Fisher Scientific, Therapy, Swedish Research Council, LSP, Coronavirus, Distinguishing, Novalis, CGMP, Network as a service, Bayer, GLOBE, List of life sciences, Karolinska Institute, Leadership, Company, Marijn Dekkers, LNP, Mindful Scientific Inc., Knowledge, RNA transfection, Moderna, Marijn, Industry, PMV, Management, Vaccine

The round was led by Novalis LifeSciences with participation from Professor Kenneth Chien, a world-renowned expert in mRNA technology and its therapeutic applications.

Key Points: 
  • The round was led by Novalis LifeSciences with participation from Professor Kenneth Chien, a world-renowned expert in mRNA technology and its therapeutic applications.
  • Existing investors, including LSP (now EQT Life Sciences), PMV, Grand Pharma, Fund+, Omega Fund, and others, also participated in the financing.
  • In addition, eTheRNA announced the departure of its CEO, Steven Powell, and the appointment of current COO, Bernard Sagaert, as interim-CEO.
  • "Similarly, I am delighted to welcome Marijn and Kenneth, both of whom bring extraordinary skills to the board of eTheRNA.